It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two ...

A significant player in the Belgian biotech industry, Confo Therapeutics has devised a technology to keep GPCRs stable, enabling the mass screening and identification of GPCRs in different diseases.

DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

Viking Therapeutics Inc (NASDAQ:VKTX) reported positive data from four clinical programs, including VK2735 for obesity and VK2809 for NASH and fibrosis. The Phase II VENTURE trial for VK2735 ...

Seaport Therapeutics, the startup launched earlier this year by the team behind Karuna Therapeutics, has raised another $225 million just six months after its most recent fundraising round.

https://www.tipranks.com/news/the-fly/integra-lifesciences-price-target-raised-to-22-from-16-at-citi Kazia Therapeutics (KZIA) has released an update. Kazia ...

Confo Therapeutics is a drug discovery company building a pipeline of GPCR targeted therapeutics addressing unmet medical need. The company was founded in 2015 as a spin-off from the Vrije ...